Merck & Company Inc (MRK)vsSera Prognostics Inc (SERA)
MRK
Merck & Company Inc
$141.94
+0.60%
HEALTHCARE · Cap: $350.19B
SERA
Sera Prognostics Inc
$2.07
+0.98%
HEALTHCARE · Cap: $78.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 95098470% more annual revenue ($66.57B vs $70,000). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
SERA
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.5%
Fair Value
$83.26
Current Price
$141.94
$58.68 premium
Margin of Safety
-73.8%
Fair Value
$1.49
Current Price
$2.07
$0.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 76.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.4x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 76.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 112.7x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while SERA is a hypergrowth play — different risk/reward profiles.
SERA carries more volatility with a beta of 1.06 — expect wider price swings.
SERA is growing revenue faster at 76.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering force in maternal-fetal health, focusing on cutting-edge diagnostic solutions designed to enhance pregnancy outcomes. Its flagship product, the PreTRM test, harnesses a unique biomarker platform to accurately evaluate the risk of preterm birth, enabling healthcare providers to implement timely and impactful interventions. With a steadfast commitment to advancing prenatal diagnostics and addressing pivotal health challenges, Sera is strategically positioned for significant growth within the maternal health sector, offering investors compelling opportunities for long-term value creation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?